Engineering death resistance in CHO cells for improved perfusion culture

The reliable and cost-efficient manufacturing of monoclonal antibodies (mAbs) is essential to fulfil their ever-growing demand. Cell death in bioreactors reduces productivity and product quality, and is largely attributed to apoptosis. In perfusion bioreactors, this leads to the necessity of a bleed...

Full description

Saved in:
Bibliographic Details
Published inmAbs Vol. 14; no. 1; p. 2083465
Main Authors MacDonald, Michael A., Nöbel, Matthias, Martínez, Verónica S., Baker, Kym, Shave, Evan, Gray, Peter P., Mahler, Stephen, Munro, Trent, Nielsen, Lars K., Marcellin, Esteban
Format Journal Article
LanguageEnglish
Published Taylor & Francis 31.12.2022
Taylor & Francis Group
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The reliable and cost-efficient manufacturing of monoclonal antibodies (mAbs) is essential to fulfil their ever-growing demand. Cell death in bioreactors reduces productivity and product quality, and is largely attributed to apoptosis. In perfusion bioreactors, this leads to the necessity of a bleed stream, which negatively affects the overall process economy. To combat this limitation, death-resistant Chinese hamster ovary cell lines were developed by simultaneously knocking out the apoptosis effector proteins Bak1, Bax, and Bok with CRISPR technology. These cell lines were cultured in fed-batch and perfusion bioreactors and compared to an unmodified control cell line. In fed-batch, the death-resistant cell lines showed higher cell densities and longer culture durations, lasting nearly a month under standard culture conditions. In perfusion, the death-resistant cell lines showed slower drops in viability and displayed an arrest in cell division after which cell size increased instead. Pertinently, the death-resistant cell lines demonstrated the ability to be cultured for several weeks without bleed, and achieved similar volumetric productivities at lower cell densities than that of the control cell line. Perfusion culture reduced fragmentation of the mAb produced, and the death-resistant cell lines showed increased glycosylation in the light chain in both bioreactor modes. These data demonstrate that rationally engineered death-resistant cell lines are ideal for mAb production in perfusion culture, negating the need to bleed the bioreactor whilst maintaining product quantity and quality.
AbstractList The reliable and cost-efficient manufacturing of monoclonal antibodies (mAbs) is essential to fulfil their ever-growing demand. Cell death in bioreactors reduces productivity and product quality, and is largely attributed to apoptosis. In perfusion bioreactors, this leads to the necessity of a bleed stream, which negatively affects the overall process economy. To combat this limitation, death-resistant Chinese hamster ovary cell lines were developed by simultaneously knocking out the apoptosis effector proteins Bak1, Bax, and Bok with CRISPR technology. These cell lines were cultured in fed-batch and perfusion bioreactors and compared to an unmodified control cell line. In fed-batch, the death-resistant cell lines showed higher cell densities and longer culture durations, lasting nearly a month under standard culture conditions. In perfusion, the death-resistant cell lines showed slower drops in viability and displayed an arrest in cell division after which cell size increased instead. Pertinently, the death-resistant cell lines demonstrated the ability to be cultured for several weeks without bleed, and achieved similar volumetric productivities at lower cell densities than that of the control cell line. Perfusion culture reduced fragmentation of the mAb produced, and the death-resistant cell lines showed increased glycosylation in the light chain in both bioreactor modes. These data demonstrate that rationally engineered death-resistant cell lines are ideal for mAb production in perfusion culture, negating the need to bleed the bioreactor whilst maintaining product quantity and quality.
Author Nöbel, Matthias
Gray, Peter P.
MacDonald, Michael A.
Baker, Kym
Munro, Trent
Martínez, Verónica S.
Mahler, Stephen
Shave, Evan
Nielsen, Lars K.
Marcellin, Esteban
Author_xml – sequence: 1
  givenname: Michael A.
  orcidid: 0000-0002-2123-096X
  surname: MacDonald
  fullname: MacDonald, Michael A.
  organization: ARC Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, Australia, Thermo Fisher Scientific, Woolloongabba, Brisbane, Australia
– sequence: 2
  givenname: Matthias
  orcidid: 0000-0001-6996-6776
  surname: Nöbel
  fullname: Nöbel, Matthias
  organization: ARC Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, Australia, Thermo Fisher Scientific, Woolloongabba, Brisbane, Australia
– sequence: 3
  givenname: Verónica S.
  surname: Martínez
  fullname: Martínez, Verónica S.
  organization: ARC Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, Australia
– sequence: 4
  givenname: Kym
  surname: Baker
  fullname: Baker, Kym
  organization: Thermo Fisher Scientific, Woolloongabba, Brisbane, Australia
– sequence: 5
  givenname: Evan
  surname: Shave
  fullname: Shave, Evan
  organization: Thermo Fisher Scientific, Woolloongabba, Brisbane, Australia
– sequence: 6
  givenname: Peter P.
  surname: Gray
  fullname: Gray, Peter P.
  organization: ARC Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, Australia
– sequence: 7
  givenname: Stephen
  orcidid: 0000-0003-2403-1437
  surname: Mahler
  fullname: Mahler, Stephen
  organization: ARC Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, Australia
– sequence: 8
  givenname: Trent
  orcidid: 0000-0003-1987-2020
  surname: Munro
  fullname: Munro, Trent
  organization: ARC Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, Australia, National Biologics Facility, The University of Queensland, Saint Lucia, Queensland, Australia
– sequence: 9
  givenname: Lars K.
  surname: Nielsen
  fullname: Nielsen, Lars K.
  organization: ARC Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, Australia, Queensaldn Metabolomics and Proteomics, The University of Queensland, Saint Lucia, Queensland, Australia, The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kongens Lyngby, Denmark
– sequence: 10
  givenname: Esteban
  orcidid: 0000-0003-3173-7956
  surname: Marcellin
  fullname: Marcellin, Esteban
  organization: ARC Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, Australia, Queensaldn Metabolomics and Proteomics, The University of Queensland, Saint Lucia, Queensland, Australia
BookMark eNpVkc9LYzEQx4O4rNr1TxBy9NKa38m7CFJ0Kwhe3HNIk0mNvCY1eU_Y_377tlVwDjPDzPAZZr4X6DSXDAhdUbKgxJAb2glGjGILRtjkDBdKnqDzqT4nRpPTr1yxM3TZ2huZTBOqyU90xqXm2jB5jlb3eZMyQE15gwO44RVXaKkNLnvAKePl6hl76PuGY6k4bXe1fEDAO6hxbKlk7Md-GCv8Qj-i6xtcHuMM_Xm4f1mu5k_Pvx-Xd09zL6QY5k4awaAjnAQd1nrdCUO9W8uoiQ5ROEU0lRE4BEm7CNJ7QxnXUQE3nmnNZ-jxwA3FvdldTVtX_9rikv1fKHVjXR2S78EqyTrFnOFUMKEV2R8cpAZnICgnedyzbg-s3bjeQvCQh-r6b9DvnZxe7aZ82I5xafZHzND1EVDL-whtsNvUpm-5DGVslilDCVeUT6PyMOpraa1C_FpDiZ1EtZ-i2klUexSV_wMzEJQs
CitedBy_id crossref_primary_10_1002_btpr_3471
crossref_primary_10_1007_s00253_024_13110_9
crossref_primary_10_1007_s00253_024_13008_6
crossref_primary_10_1002_bit_28613
crossref_primary_10_1002_btpr_3354
crossref_primary_10_3389_fbioe_2023_1112349
Cites_doi 10.1002/btpr.2415
10.1038/cdd.2017.179
10.1038/cdd.2013.10
10.1002/bit.26985
10.1002/btpr.2723
10.1002/bit.27269
10.1016/j.aca.2011.10.022
10.1086/528801
10.1002/biot.201500027
10.1016/j.ymben.2006.05.005
10.1016/j.jbiotec.2019.08.001
10.1186/s40643-020-00304-y
10.1002/btpr.2537
10.1002/bit.26969
10.1038/nbt.1932
10.1021/acssynbio.0c00322
10.1080/19420862.2020.1770669
10.1007/s00253-017-8312-7
10.1007/s00449-017-1790-2
10.1023/B:APPT.0000045792.63249.5a
10.1038/s41418-019-0327-4
10.1002/(SICI)1097-0290(19990605)63:5<529::AID-BIT3>3.0.CO;2-X
10.1002/btpr.2973
10.1002/biot.201500082
10.1002/biot.201700722
10.1002/bit.22541
10.1080/07388551.2021.1998821
10.1073/pnas.94.23.12401
10.1111/febs.14186
10.1038/cdd.2017.186
10.1016/S0167-7799(00)88926-X
10.1002/bit.27747
10.1002/biot.201700733
10.1002/btpr.2946
10.1016/S1473-3099(19)30634-6
10.1002/bit.21479
10.1023/A:1008055702079
10.1016/j.cell.2016.02.026
10.1016/j.biotechadv.2019.02.012
10.1002/biot.201800070
10.1002/btpr.1722
10.1007/s10616-010-9274-0
10.1016/j.copbio.2017.11.015
10.1002/btpr.2472
10.1002/bit.28062
10.1101/cshperspect.a008714
10.1016/j.copbio.2013.02.007
10.1016/j.jbiotec.2016.06.019
10.1080/19420862.2019.1652075
10.1016/j.ymben.2017.09.010
10.1002/biot.201700721
10.1002/bit.27548
ContentType Journal Article
Copyright 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. 2022 The Author(s)
Copyright_xml – notice: 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. 2022 The Author(s)
DBID AAYXX
CITATION
7X8
5PM
DOA
DOI 10.1080/19420862.2022.2083465
DatabaseName CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList

Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate M. A. MACDONALD ET AL
EISSN 1942-0870
EndPage 2083465
ExternalDocumentID oai_doaj_org_article_652962a831424760825d57ea8ed6a53f
10_1080_19420862_2022_2083465
GroupedDBID ---
00X
0YH
53G
AAYXX
ABCCY
ABFIM
ABPEM
ACGFS
ACTIO
ADBBV
ADCVX
AEISY
AENEX
AIJEM
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AQRUH
BABNJ
BAWUL
BLEHA
CCCUG
CITATION
DGEBU
DIK
DKSSO
E3Z
EBS
EMOBN
F5P
GROUPED_DOAJ
H13
HYE
KTTOD
KYCEM
LJTGL
M4Z
O9-
OK1
RPM
SV3
TDBHL
TFL
TFT
TFW
TR2
7X8
5PM
AEGYZ
ID FETCH-LOGICAL-c454t-a5842e9030d7db7b9481cab5f707df4a60715fe3ed519fe5cc81237f6e38c2773
IEDL.DBID RPM
ISSN 1942-0862
IngestDate Tue Oct 22 15:14:31 EDT 2024
Tue Sep 17 21:29:05 EDT 2024
Wed Dec 04 01:08:36 EST 2024
Fri Dec 06 03:26:48 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c454t-a5842e9030d7db7b9481cab5f707df4a60715fe3ed519fe5cc81237f6e38c2773
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Co-principal authors
ORCID 0000-0003-2403-1437
0000-0003-1987-2020
0000-0001-6996-6776
0000-0002-2123-096X
0000-0003-3173-7956
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9235890/
PMID 35737825
PQID 2681036130
PQPubID 23479
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_652962a831424760825d57ea8ed6a53f
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9235890
proquest_miscellaneous_2681036130
crossref_primary_10_1080_19420862_2022_2083465
PublicationCentury 2000
PublicationDate 2022-12-31
PublicationDateYYYYMMDD 2022-12-31
PublicationDate_xml – month: 12
  year: 2022
  text: 2022-12-31
  day: 31
PublicationDecade 2020
PublicationTitle mAbs
PublicationYear 2022
Publisher Taylor & Francis
Taylor & Francis Group
Publisher_xml – name: Taylor & Francis
– name: Taylor & Francis Group
References e_1_3_5_29_1
e_1_3_5_27_1
e_1_3_5_25_1
e_1_3_5_23_1
e_1_3_5_44_1
e_1_3_5_46_1
e_1_3_5_3_1
e_1_3_5_40_1
e_1_3_5_42_1
e_1_3_5_9_1
e_1_3_5_21_1
e_1_3_5_5_1
e_1_3_5_7_1
e_1_3_5_18_1
e_1_3_5_39_1
e_1_3_5_16_1
e_1_3_5_37_1
e_1_3_5_14_1
e_1_3_5_35_1
e_1_3_5_12_1
e_1_3_5_33_1
e_1_3_5_50_1
e_1_3_5_52_1
e_1_3_5_54_1
e_1_3_5_10_1
e_1_3_5_31_1
e_1_3_5_28_1
e_1_3_5_26_1
e_1_3_5_24_1
e_1_3_5_22_1
e_1_3_5_45_1
e_1_3_5_47_1
e_1_3_5_49_1
e_1_3_5_2_1
e_1_3_5_41_1
e_1_3_5_43_1
e_1_3_5_8_1
e_1_3_5_20_1
e_1_3_5_4_1
e_1_3_5_6_1
e_1_3_5_17_1
e_1_3_5_38_1
e_1_3_5_15_1
e_1_3_5_13_1
e_1_3_5_36_1
e_1_3_5_11_1
e_1_3_5_34_1
e_1_3_5_19_1
e_1_3_5_51_1
e_1_3_5_53_1
e_1_3_5_32_1
e_1_3_5_30_1
Wolf MKF (e_1_3_5_48_1) 2018
References_xml – ident: e_1_3_5_15_1
  doi: 10.1002/btpr.2415
– ident: e_1_3_5_31_1
  doi: 10.1038/cdd.2017.179
– ident: e_1_3_5_39_1
  doi: 10.1038/cdd.2013.10
– ident: e_1_3_5_12_1
  doi: 10.1002/bit.26985
– ident: e_1_3_5_13_1
  doi: 10.1002/btpr.2723
– ident: e_1_3_5_2_1
  doi: 10.1002/bit.27269
– ident: e_1_3_5_46_1
  doi: 10.1016/j.aca.2011.10.022
– ident: e_1_3_5_53_1
  doi: 10.1086/528801
– ident: e_1_3_5_20_1
  doi: 10.1002/biot.201500027
– ident: e_1_3_5_37_1
  doi: 10.1016/j.ymben.2006.05.005
– ident: e_1_3_5_10_1
  doi: 10.1016/j.jbiotec.2019.08.001
– ident: e_1_3_5_17_1
  doi: 10.1186/s40643-020-00304-y
– ident: e_1_3_5_49_1
  doi: 10.1002/btpr.2537
– ident: e_1_3_5_36_1
  doi: 10.1002/bit.26969
– ident: e_1_3_5_22_1
  doi: 10.1038/nbt.1932
– ident: e_1_3_5_21_1
  doi: 10.1021/acssynbio.0c00322
– ident: e_1_3_5_18_1
  doi: 10.1080/19420862.2020.1770669
– ident: e_1_3_5_51_1
  doi: 10.1007/s00253-017-8312-7
– ident: e_1_3_5_16_1
  doi: 10.1007/s00449-017-1790-2
– ident: e_1_3_5_8_1
  doi: 10.1023/B:APPT.0000045792.63249.5a
– ident: e_1_3_5_41_1
  doi: 10.1038/s41418-019-0327-4
– start-page: 1700722
  year: 2018
  ident: e_1_3_5_48_1
  article-title: Improved performance in mammalian cell perfusion cultures by growth inhibition
  publication-title: Biotechnol J
  contributor:
    fullname: Wolf MKF
– ident: e_1_3_5_6_1
  doi: 10.1002/(SICI)1097-0290(19990605)63:5<529::AID-BIT3>3.0.CO;2-X
– ident: e_1_3_5_11_1
  doi: 10.1002/btpr.2973
– ident: e_1_3_5_26_1
  doi: 10.1002/biot.201500082
– ident: e_1_3_5_28_1
  doi: 10.1002/biot.201700722
– ident: e_1_3_5_34_1
  doi: 10.1002/bit.22541
– ident: e_1_3_5_9_1
  doi: 10.1080/07388551.2021.1998821
– ident: e_1_3_5_38_1
  doi: 10.1073/pnas.94.23.12401
– ident: e_1_3_5_32_1
  doi: 10.1111/febs.14186
– ident: e_1_3_5_30_1
  doi: 10.1038/cdd.2017.186
– ident: e_1_3_5_43_1
  doi: 10.1016/S0167-7799(00)88926-X
– ident: e_1_3_5_47_1
  doi: 10.1002/bit.27747
– ident: e_1_3_5_50_1
  doi: 10.1002/biot.201700733
– ident: e_1_3_5_45_1
  doi: 10.1002/btpr.2946
– ident: e_1_3_5_52_1
  doi: 10.1016/S1473-3099(19)30634-6
– ident: e_1_3_5_7_1
  doi: 10.1002/bit.21479
– ident: e_1_3_5_5_1
  doi: 10.1023/A:1008055702079
– ident: e_1_3_5_40_1
  doi: 10.1016/j.cell.2016.02.026
– ident: e_1_3_5_29_1
  doi: 10.1016/j.biotechadv.2019.02.012
– ident: e_1_3_5_42_1
  doi: 10.1002/biot.201800070
– ident: e_1_3_5_35_1
  doi: 10.1002/btpr.1722
– ident: e_1_3_5_3_1
  doi: 10.1007/s10616-010-9274-0
– ident: e_1_3_5_25_1
  doi: 10.1016/j.copbio.2017.11.015
– ident: e_1_3_5_27_1
  doi: 10.1002/btpr.2472
– ident: e_1_3_5_44_1
  doi: 10.1002/bit.28062
– ident: e_1_3_5_33_1
  doi: 10.1101/cshperspect.a008714
– ident: e_1_3_5_24_1
  doi: 10.1016/j.copbio.2013.02.007
– ident: e_1_3_5_14_1
  doi: 10.1016/j.jbiotec.2016.06.019
– ident: e_1_3_5_19_1
  doi: 10.1080/19420862.2019.1652075
– ident: e_1_3_5_4_1
  doi: 10.1016/j.ymben.2017.09.010
– ident: e_1_3_5_54_1
  doi: 10.1002/biot.201700721
– ident: e_1_3_5_23_1
  doi: 10.1002/bit.27548
SSID ssj0000070170
Score 2.4113579
Snippet The reliable and cost-efficient manufacturing of monoclonal antibodies (mAbs) is essential to fulfil their ever-growing demand. Cell death in bioreactors...
SourceID doaj
pubmedcentral
proquest
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
StartPage 2083465
SubjectTerms bioprocessing
cell line development
genetic engineering
mAb glycosylation
mAb manufacturing
perfusion
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrZ07b4MwEMetqlOXqk-VvuRKVabQEGxjGNuoEerQZkikbMjYZzULifIY8u3r49HA1KULgwEBZ5v7n-37mZBnxUJruTR-wIfK5yYWuM0L-FFiOOfgPCaUq3w_o3TGP-Zi3trqC9eEVXjgynCDCCcGQxUzTMmSEUY0RkhQMZhICWbLv28QtoKpSvhKBMOUU8o89FG3N-k7cTDAMixy4WGIh5hxdC4tx1Ty-zuis7tksuWDxmfktBaP9LV66XNyBMUF6U0q-vS-T6eHZKpNn_bo5MCl3l-StMUepAalH3WxNupHV_F0UdBR-kVxIH9DnZKli3K4AQxdwdrucFCNVpgOuCKz8ft0lPr1Rgq-5oJvfeVURgiJ689GmlzmSGjRKhdWBtJYrpAxJywwME7PWRBaO7fPpI2AxTqUkl2T42JZwA2hwTDHO3WUB8CHmicIJI250loIpqX0yEtjxWxV8TKyYY0hbcyeodmz2uweeUNb_16MuOuywDWCrG4E2V-NwCNPTU1lrnugqVQBy90mC5G3xjBI8ojsVGHnid0zxeK7BG0nmEecBLf_8Yp35AQ_u2JE3pPj7XoHD07PbPPHsun-AAj-7k4
  priority: 102
  providerName: Directory of Open Access Journals
Title Engineering death resistance in CHO cells for improved perfusion culture
URI https://search.proquest.com/docview/2681036130
https://pubmed.ncbi.nlm.nih.gov/PMC9235890
https://doaj.org/article/652962a831424760825d57ea8ed6a53f
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07b9swED4knroUSR-o8wILFJksWxZJURoTo4FRoK0HB8gmUOSxMZDIhh-D_314lBRbaxcNlKgHPwr33fHuI8APzRPnhLJRLMY6EjaTtM0LRmluhRDoLSaGLN8_6fRR_HqSTycg21qYkLRvysWwenkdVovnkFu5ejWjNk9sNPs9yam-M49Hp3Dqb3bkotecV5EmTFhNFklElL2t3MniEbVRk_cMEzpkXKS0ew2XintjKTvmKaj4d6hnN3HyyBI9nMHHhkKyu_pVz-EEq09wO6s1qPcDNj-UVG0G7JbNDurU-88wPVIgZJYIIPMeN7FIDz9bVGwy_csonL9hns-yRQg6oGUrXLsdhdZYLdaBX-Dx4ed8Mo2a7RQiI6TYRtpzjQRz_1dbZUtVkk6L0aV0KlbWCU1Kc9IhR-tZnUNpjDf-XLkUeWYSpfhX6FXLCr8Bi8cl9TRpGaMYG5GTLGkmtDFScqNUH4btKBarWjWjGDdipC0CBSFQNAj04Z7G-v1iEr0ODcv1v6KBvkhpjTjRGafqPJWSc2ulQp2hTbXkrg_fW6QK_5PQUOkKl7tNkZDqGidXqQ-qA2Hnid0zfvYFue1mtl38d89L-EDfWstDXkFvu97htacy2_ImhABuwgR-A6V58SM
link.rule.ids 230,314,727,780,784,864,885,2102,27924,27925,53791,53793
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3Lb5wwEIdHaXpoL1XTh7p9xZWqnMIuYBvDsV0lIm2S7mEj5WYZe0hXatjVPg757-sx0CzXXjgYEOAxmt_YM58Bvhqe1rVQLopFYiLhcknbvGCUFU4Igd5jYsjyvc7KG_HjVt4egOxrYULSvq0W4-bP_bhZ_A65lat7O-nzxCazq2lB9Z1FPHkCTyVXRbIXpLeqVxEVJqwnizQi0d7X7uTxhNqoyceGKR1yLjLav4ZLxb27lAMHFTj-A_E5TJ3c80XnL-FFJyLZt_Zlj-AAm1dwMmsp1A-nbP5YVLU5ZSds9sinfngN5R6DkDmSgMzH3KQj_QBgi4ZNy1-MJvQ3zCtatgjTDujYCtf1jibXWIvrwDdwc342n5ZRt6FCZIUU28h4tZFi4f9rp1ylKiK1WFPJWsXK1cIQa07WyNF5XVejtNa7f67qDHluU6X4Wzhslg2-AxYnFd1psypGkVhREJg0F8ZaKblVagTjvhf1quVm6KTDkfYW0GQB3VlgBN-pr_9dTNjr0LBc3-nO-DqjVeLU5Jzq81RG4a2TCk2OLjOS1yP40ltK-9-Euso0uNxtdErcNU7B0gjUwISDJw7P-PEXgNvdeHv_33cew7NyfnWpLy-uf36A5_TdLSzyIxxu1zv85IXNtvochvFfz9fzgw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDCa2Dhh2GfbEsu6hAUNPdexYkmUft2xB9upyaIHeBFmiugCrE-Rx6L-vKNtrfN3FB9qCbZECP0rkR4CPhufeC-WSTExMIlwpqc0LJkXlhBAYPCbGLN-zYn4hvl_Ky4NWXzFp39bLcfP3etws_8TcyvW1Tfs8sXTxa1pRfWeVpWvn0_vwQPJgZAeBeot8FTHDxDNlkScE3Pv6nTJLSUaiEB_mdCm5KKiHDZeKB5cpB04qcvkPAOgwffLAH82ewOMOSLJP7Qc_hXvYPIOTRctEfXPKzu8Kq7an7IQt7jiqb57D_ICHkDmCgSzE3YQlgxGwZcOm89-MNvW3LKBatoxbD-jYGjd-TxtsrKXswBdwMft6Pp0nXVOFxAopdokJiCPHKqxtp1ytamJrsaaWXmXKeWGIb0565OgCtvMorQ0QgCtfIC9trhR_CUfNqsFXwLJJTSNtUWcoJlZURE5aCmOtlNwqNYJxP4t63XJn6ElHSdprQJMGdKeBEXymuf73MFFfR8Fqc6U7A9AFnRTnpuRUo6cKCnGdVGhKdIWR3I_gQ68pHZYKTZVpcLXf6py41zgFTCNQAxUO3ji8E2wwkm53Nvf6v0e-h4eLLzP989vZj2N4RL_d8kW-gaPdZo9vA7bZ1e-iFd8CY7r0lg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Engineering+death+resistance+in+CHO+cells+for+improved+perfusion+culture&rft.jtitle=mAbs&rft.au=Michael+A.+MacDonald&rft.au=Matthias+N%C3%B6bel&rft.au=Ver%C3%B3nica+S.+Mart%C3%ADnez&rft.au=Kym+Baker&rft.date=2022-12-31&rft.pub=Taylor+%26+Francis+Group&rft.issn=1942-0862&rft.eissn=1942-0870&rft.volume=14&rft.issue=1&rft_id=info:doi/10.1080%2F19420862.2022.2083465&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_652962a831424760825d57ea8ed6a53f
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1942-0862&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1942-0862&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1942-0862&client=summon